The use of the OMERACT ultrasound tenosynovitis scoring system in multicenter clinical trials

Mads Ammitzbøll-Danielsen; Mikkel Østergaard; Esperanza Naredo; Annamaria Iagnocco; Ingrid Möller; Maria Antonietta D'Agostino; Frédérique Gandjbakhch; Lene Terslev

doi:10.3899/jrheum.170501

The use of the OMERACT ultrasound tenosynovitis scoring system in multicenter clinical trials

Mads Ammitzbøll-Danielsen^*, Mikkel Østergaard, Esperanza Naredo, Annamaria Iagnocco, Ingrid Möller, Maria Antonietta D'Agostino, Frédérique Gandjbakhch, Lene Terslev

^*Corresponding author af dette arbejde

Institut for Klinisk Medicin

3 Citationer (Scopus)

Abstract

Objective: To test the sensitivity to change of the Outcome Measures in Rheumatology Clinical Trials (OMERACT) ultrasound (US) scoring system for tenosynovitis when applied in a multicenter design. Methods: RA patients with US-verified tenosynovitis were recruited when scheduled for treatment intensification. Tenosynovitis was assessed at baseline, and 3 and 6 months followup, using the semiquantitative OMERACT scoring system. Results: Expressed in median (25th; 75th percentiles), the overall greyscale and Doppler score decreased significantly from baseline at 4 (2; 7) and 3 (2; 6), to 6 months at 2 (0; 3) and 0 (0; 1, p < 0.01), respectively, and showed high responsiveness (standardized response mean = 0.8). Conclusion: The OMERACT US scoring system for tenosynovitis showed high responsiveness, supporting its use for diagnosing and monitoring tenosynovitis in multicenter trials.

Originalsprog	Engelsk
Tidsskrift	Journal of Rheumatology
Vol/bind	45
Udgave nummer	2
Sider (fra-til)	165-169
ISSN	0315-162X
DOI	https://doi.org/10.3899/jrheum.170501
Status	Udgivet - 2018

Adgang til dokumentet

10.3899/jrheum.170501

Citationsformater

@article{77871381b65a4cf0b8a6088d0930ef0b,

title = "The use of the OMERACT ultrasound tenosynovitis scoring system in multicenter clinical trials",

abstract = "Objective: To test the sensitivity to change of the Outcome Measures in Rheumatology Clinical Trials (OMERACT) ultrasound (US) scoring system for tenosynovitis when applied in a multicenter design. Methods: RA patients with US-verified tenosynovitis were recruited when scheduled for treatment intensification. Tenosynovitis was assessed at baseline, and 3 and 6 months followup, using the semiquantitative OMERACT scoring system. Results: Expressed in median (25th; 75th percentiles), the overall greyscale and Doppler score decreased significantly from baseline at 4 (2; 7) and 3 (2; 6), to 6 months at 2 (0; 3) and 0 (0; 1, p < 0.01), respectively, and showed high responsiveness (standardized response mean = 0.8). Conclusion: The OMERACT US scoring system for tenosynovitis showed high responsiveness, supporting its use for diagnosing and monitoring tenosynovitis in multicenter trials.",

keywords = "Omeract, Rheumatoid arthritis, Tenosynovitis, Ultrasonography",

author = "Mads Ammitzb{\o}ll-Danielsen and Mikkel {\O}stergaard and Esperanza Naredo and Annamaria Iagnocco and Ingrid M{\"o}ller and D'Agostino, {Maria Antonietta} and Fr{\'e}d{\'e}rique Gandjbakhch and Lene Terslev",

year = "2018",

doi = "10.3899/jrheum.170501",

language = "English",

volume = "45",

pages = "165--169",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology Publishing Co. Ltd.",

number = "2",

}

TY - JOUR

T1 - The use of the OMERACT ultrasound tenosynovitis scoring system in multicenter clinical trials

AU - Ammitzbøll-Danielsen, Mads

AU - Østergaard, Mikkel

AU - Naredo, Esperanza

AU - Iagnocco, Annamaria

AU - Möller, Ingrid

AU - D'Agostino, Maria Antonietta

AU - Gandjbakhch, Frédérique

AU - Terslev, Lene

PY - 2018

Y1 - 2018

N2 - Objective: To test the sensitivity to change of the Outcome Measures in Rheumatology Clinical Trials (OMERACT) ultrasound (US) scoring system for tenosynovitis when applied in a multicenter design. Methods: RA patients with US-verified tenosynovitis were recruited when scheduled for treatment intensification. Tenosynovitis was assessed at baseline, and 3 and 6 months followup, using the semiquantitative OMERACT scoring system. Results: Expressed in median (25th; 75th percentiles), the overall greyscale and Doppler score decreased significantly from baseline at 4 (2; 7) and 3 (2; 6), to 6 months at 2 (0; 3) and 0 (0; 1, p < 0.01), respectively, and showed high responsiveness (standardized response mean = 0.8). Conclusion: The OMERACT US scoring system for tenosynovitis showed high responsiveness, supporting its use for diagnosing and monitoring tenosynovitis in multicenter trials.

AB - Objective: To test the sensitivity to change of the Outcome Measures in Rheumatology Clinical Trials (OMERACT) ultrasound (US) scoring system for tenosynovitis when applied in a multicenter design. Methods: RA patients with US-verified tenosynovitis were recruited when scheduled for treatment intensification. Tenosynovitis was assessed at baseline, and 3 and 6 months followup, using the semiquantitative OMERACT scoring system. Results: Expressed in median (25th; 75th percentiles), the overall greyscale and Doppler score decreased significantly from baseline at 4 (2; 7) and 3 (2; 6), to 6 months at 2 (0; 3) and 0 (0; 1, p < 0.01), respectively, and showed high responsiveness (standardized response mean = 0.8). Conclusion: The OMERACT US scoring system for tenosynovitis showed high responsiveness, supporting its use for diagnosing and monitoring tenosynovitis in multicenter trials.

KW - Omeract

KW - Rheumatoid arthritis

KW - Tenosynovitis

KW - Ultrasonography

U2 - 10.3899/jrheum.170501

DO - 10.3899/jrheum.170501

M3 - Journal article

C2 - 29247153

AN - SCOPUS:85041654986

SN - 0315-162X

VL - 45

SP - 165

EP - 169

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 2

ER -

The use of the OMERACT ultrasound tenosynovitis scoring system in multicenter clinical trials

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater